T cell receptors, immunoregulation, and autoimmunity.
T cell receptor (TCR) peptide vaccines have proven useful in the prevention and treatment of autoimmune disease in animal models. Prospects for developing TCR peptide vaccines for human autoimmune disease are only now being explored. Preliminary indications provide cause for optimism that immunization with TCR peptides eventually will be a viable treatment option for autoimmune pathologies in humans. In the long term, development of this technology may permit reliable manipulation of T cell immunity, leading to treatments for autoimmunity, T lymphoproliferative disorders, and, in the broadest interpretation, any pathogenesis mediated by oligoclonal T cell populations.
Brostoff
S W
SW
Immune Response Corporation, Carlsbad, California 92008.
Howell
M D
MD
D000818:Animals; D001327:Autoimmune Diseases / Q000209:etiology / Q000628:therapy; D015551:Autoimmunity; D006801:Humans; D007108:Immune Tolerance; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000502:physiology*; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination
D011948:Receptors, Antigen, T-Cell